Searchable abstracts of presentations at key conferences in endocrinology

ea0050p279 | Neuroendocrinology and Pituitary | SFEBES2017

Bilateral Inferior Petrosal Sinus Sampling (BIPSS) reliably differentiates pituitary from ectopic Cushing’s syndrome, but does not predict pituitary tumour location, especially when lateralizing to the right

White Louisa , Tobin Jake , Koulouri Olympia , Powlson Andrew , Bashari Waiel , Koo Brendan , Gurnell Mark

Background: BIPSS is considered the gold-standard procedure for differentiating autonomous pituitary [Cushing’s Disease (CD)] and ectopic ACTH syndrome (EAS) sources of ACTH hypersecretion. A basal (i.e. unstimulated) pituitary:peripheral ACTH ratio >2, and/or a CRH stimulated pituitary:peripheral ACTH ratio >3, have been proposed as indicative of CD, with a range of sensitivities and specificities cited in the literature. Ad...

ea0050p279 | Neuroendocrinology and Pituitary | SFEBES2017

Bilateral Inferior Petrosal Sinus Sampling (BIPSS) reliably differentiates pituitary from ectopic Cushing’s syndrome, but does not predict pituitary tumour location, especially when lateralizing to the right

White Louisa , Tobin Jake , Koulouri Olympia , Powlson Andrew , Bashari Waiel , Koo Brendan , Gurnell Mark

Background: BIPSS is considered the gold-standard procedure for differentiating autonomous pituitary [Cushing’s Disease (CD)] and ectopic ACTH syndrome (EAS) sources of ACTH hypersecretion. A basal (i.e. unstimulated) pituitary:peripheral ACTH ratio >2, and/or a CRH stimulated pituitary:peripheral ACTH ratio >3, have been proposed as indicative of CD, with a range of sensitivities and specificities cited in the literature. Ad...

ea0037gp.21.02 | Pituitary – Diagnosis of Cushing's disease | ECE2015

Bilateral inferior petrosal sinus sampling reliably differentiates pituitary from ectopic Cushing's, but frequently fails to predict pituitary tumour location, especially when lateralizing to the right

Koulouri Olympia , Nigam Nishita , Powlson Andrew , Donnelly Neil , Mannion Richard , Pickard John , Koo Brendan , Halsall David , Gurnell Mark

Background: BIPSS remains the gold standard for differentiating pituitary and ectopic sources in ACTH-dependent Cushing’s syndrome. A pituitary:peripheral ACTH ratio >2 in the basal state, and/or >3 following CRH stimulation, is considered indicative of pituitary Cushing’s, with a range of sensitivities and specificities cited in the literature. In addition, in Cushing’s disease a peak interpetrosal gradient of >1.4 has been reported to predict the s...

ea0034p365 | Steroids | SFEBES2014

11C-metomidate PET–CT in primary hyperaldosteronism: a valuable alternative to AVS

Powlson Andrew S , Koulouri Olympia , Challis Benjamin G , Cheow H K , Buscombe John , Koo Brendan , Brown Morris J , Gurnell Mark

Although adrenal vein sampling (AVS) remains the gold-standard for distinguishing unilateral and bilateral disease in primary hyperaldosteronism (PHA), it is technically demanding and not always feasible. Metomidate (MTO), a potent inhibitor of CYP11B1 and CYP11B2, can be C11H3-labelled as a PET tracer (11C-MTO), and we have previously shown it to be an alternative to AVS for localising unilateral aldosterone-producing adenomas (APAs) (Burton <...

ea0037oc1.4 | Adrenal 1 | ECE2015

11C-metomidate PET-CT in primary aldosteronism: five possible indications for a non-invasive alternative to adrenal vein sampling

Powlson Andrew S , Koulouri Olympia , Azizan Elena , Maniero Carmela , Taylor Kevin , Aigbirhio Franklin , Koo Brendan , Cheow Heok K , Buscombe John , Gurnell Mark , Brown Morris J

Background: Adrenal vein sampling (AVS) remains the gold-standard for distinguishing unilateral and bilateral disease in primary aldosteronism (PA). However, it is invasive, technically demanding, and may yield inconclusive or equivocal results. 11C-Metomidate PET-CT (11C-MTO-PET-CT) is a non-invasive alternative to AVS for localising unilateral aldosterone-producing adenomas (APAs).Methods/patients: We report a retrospective analys...

ea0086op2.3 | Adrenal and Cardiovascular | SFEBES2022

Complete clinical cure of primary aldosteronism (PA) is predictable and sustained for at least two years

Goodchild Emily , Wu Xilin , Senanayake Russell , Bashari Waiel , Salsbury Jackie , Cabrera Claudia , Argentesi Giulia , O'Toole Samuel , MacFarlane James , Laycock Kate , Benu Daniela , Matson Matthew , Koo Brendan , Parvanta Laila , Hilliard Nick , Kosmoliaptsis Vasilis , Marker Alison , Berney Daniel , Tan Wilson , Foo Roger , Mein Charles , Wozniak Eva , Savage Emmanuel , Sahdev Anju , Bird Nicholas , Boros Istvan , Hader Stefan , Warnes Victoria , Gillett Dan , Dawnay Anne , Adeyeye Elizabeth , Prete Alessandro , Taylor Angela , Wiebke Arlt , Bhuva Anish , Aigbirhio Franklin , Manisty Charlotte , Cruickshank Kennedy , Cheow Heok , Gurnell Mark , Drake William , Brown Morris

Introduction: In a prospective within-patient study (MATCH) 11C-metomidate PET-CT (MTO) was an accurate non-invasive alternative to adrenal vein sampling in the detection of unilateral PA1. Post-adrenalectomy (ADX), 24/78 (30%) patients achieved complete clinical success (PASO consensus) at 6 months, but 75% achieved reduction in B-type natriuretic peptide (BNP).Aim: To determine: 1. the number of patients who sustain complete clinical success...